Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Clinical trial NCT01286987 · COMPLETED

Trial details

NCT number: NCT01286987
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced or Recurrent Solid Tumors Breast Neoplasms Ovarian Cancer, Epithelial Ewing Sarcoma Small Cell Lung Carcinoma Prostate Cancer Pancreas Cancer

Start date: 2011-01-03
Primary completion: 2015-03-31
Enrollment: 113

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.